Reassessment of reimbursement status of the remaining subgroups of ATC group C
The Danish Medicines Agency previously notified companies and a number of scientific societies and patient organisations about which ATC groups and subgroups would be the first to be reassessed, cf. the fact box to the right. During autumn, we expect to start reassessing reimbursement status of the remaining subgroups of ATC group C:
- C01: Medicinal products for cardiac therapy
- C02: Antihypertensives
- C04: Peripheral vasodilators
- C05: Vasoprotectives
For further information, please contact the Reimbursement Department, email@example.com.
The Danish Medicines Agency, 4 July 2006